Navigation Links
GlySure Secures $10.9 Million in Series C Financing Round
Date:1/9/2012

OXFORD, England, January 9, 2012 /PRNewswire/ --

GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced the close of its $10.9 million Series C financing round. GlySure will use this funding to complete clinical trials to supportregulatory approval in the United States and Europe.

The financing round was supported by Morningside Venture, as well as existing investors Amadeus Capital Partners, Chester Investments and Delta Partners. Since its foundation in May 2006, GlySure has secured a total of $19.5 million in venture capital funding.

"We are excited about the opportunity to support GlySure's regulatory trials," said Reenie McCarthy, representing Morningside Venture. "There is a significant unmet need for continuous glucose monitoring in critical care, and the results from GlySure's initial ICU trials show that the company is on track to deliver the performance and ease-of-use required to enable clinicians to effectively implement Tight Glycemic Control."

GlySure recently completed initialhuman use trials on over 90 intensive care patients. The trials demonstrated that the GlySure system can accurately measure blood glucose levels across the entire human physiological range for the duration of a patient's stay in the Intensive Care Unit(ICU).

"This new financing round recognizes not only the significant clinical results, but also the management team's capital efficiency and ability to cost effectively deliver a product with the potential to improve outcomes for over 8 million ICU patients annually," added Dr. Joey Mason, partner at Delta Partners and a director of GlySure.

"There have been over 100 publications demonstrating the ability of Tight Glycemic Control to improve outcomes and reduce cost in the ICU," said Chris Jones, GlySure CEO. "We are grateful for the support of our existing and new investors and look forward to completing our regulatory trials so that we can bring intensive care units a system that will allow them to deliver on the decade-long promise of Tight Glycemic Control."

About GlySure:

GlySure has developed a continuous intravascular glucose monitoring system using a proprietary optical fluorescence sensor to meet the $2B+ worldwide demand for implementation of Tight Glycemic Control (TGC) in the hospital Intensive Care Unit (ICU).  GlySure was founded in 2006, it is based in Abingdon, Oxfordshire, England and it has 16 employees. http://www.glysure.com.


'/>"/>
SOURCE GlySure
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CEL-SCI Secures Manufacturing Facility for Multikine Cancer Drug
2. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
3. GeoVax Secures $10 Million Financing Commitment
4. Alexion Secures U.S. Patent for ALXN6000, a First-In-Class Anti-CD200 Monoclonal Antibody
5. Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials
6. ALung Secures $2.5 Million
7. Luminous Medical, Inc. Secures Exclusive Rights to Glucose Sensor for Its Automated Glucose Monitor
8. EnzySurge, Maker of DermaStream(R) Secures US$2.5 Million in Private Capital
9. HealthWarehouse.com, Inc. Secures $1 Million in Debt Financing
10. Poniard Pharmaceuticals Secures $20 Million Committed Equity Financing Facility
11. TransMedics, Inc. Secures $36 Million Round of Financing Lead by Foundation Capital and Kleiner Perkins Caufield & Byers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/5/2017)... , Sept. 5, 2017  Just 18 months ... Insight is pleased to announce the appointment of three ... Tammy Wynne , Dominic Jones-Phillips and ... industry. Tammy ... team of market access writers. She has over ten ...
(Date:9/1/2017)... 2017  Bayer will present the latest research from across ... Oncology (ESMO) 2017 Congress, September 8-12 in Madrid, ... and clinical data on Bayer,s marketed portfolio and late-stage compounds ... "We value the opportunity ... research at ESMO," said Carsten Brunn , Head of ...
(Date:8/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will present at the ... in New York . John Greisch ... present at 11:05 a.m. Eastern Time. The ... A recorded replay will be available one hour after the ... About Hill-Rom Holdings, Inc. ...
Breaking Medicine Technology:
(Date:9/19/2017)... ... 2017 , ... The Lymphoma Research Foundation (LRF) – the ... the lymphoma community through a comprehensive series of education programs, outreach initiatives and ... Swirl: A Wine Tasting Event series on Thursday, October 26, 2017. Hosted at ...
(Date:9/19/2017)... ... 19, 2017 , ... The American College of Lifestyle ... recently formed Corporate Roundtable, a group of individuals and organizations whose collective vision ... Canyon Ranch is a unique collection of lifestyle-based immersion vacation settings and programs ...
(Date:9/19/2017)... (PRWEB) , ... September 19, 2017 , ... ... issued a rallying cry to Americans to watch for the discomforts and hidden ... young athletes to senior citizens, everyone is at risk for developing fungal infections ...
(Date:9/19/2017)... ... September 19, 2017 , ... Leonard I. Linkow, DDS, DMSC, sets ... (published by Xlibris on July of 2014). This book details the recent advances and ... approaches that benefit people who have lost all of their natural teeth . ...
(Date:9/19/2017)... Va (PRWEB) , ... September 19, 2017 , ... The ... the use of health IT to create efficiencies in healthcare information exchange and a ... the release of their latest industry white paper, entitled Barriers to Adoption of ...
Breaking Medicine News(10 mins):